Hera Fertility has been selected for the Mayo Clinic Platform Accelerate program, a competitive initiative that connects health technology companies with Mayo Clinic’s clinical data infrastructure and research expertise to validate artificial intelligence models in real-world healthcare settings. The selection positions Hera Fertility to advance the clinical validation of its AI-driven male fertility assessment tools, moving the technology from algorithmic development toward the evidence-based foundation required for integration into clinical practice.
The Mayo Clinic Platform Accelerate program provides participating companies with access to Mayo Clinic’s de-identified clinical datasets, research collaboration resources, and the institutional credibility associated with validation work conducted in partnership with one of the world’s most recognized medical research institutions. Selection is competitive and reflects an assessment of the technology's scientific merit, the significance of the clinical problem being addressed, and the potential for the validated solution to improve patient outcomes at scale. For Hera Fertility, selection represents external confirmation that its AI approach to male fertility assessment meets the threshold for rigorous clinical investigation.
Male factor infertility contributes to approximately half of all infertility cases globally, yet it has historically received less diagnostic investment and clinical attention than female factor infertility. Standard semen analysis, the primary diagnostic tool for male fertility evaluation, provides data on sperm count, motility, and morphology, but does not produce a comprehensive assessment of fertility potential from those parameters alone. Hera Fertility’s AI models are designed to extract additional predictive signal from semen analysis data, generating a more informative output than conventional interpretation of the same underlying measurements.
“Being selected for the Mayo Clinic Platform Accelerate program is a significant validation of the scientific direction we’ve been building toward,” said Thiv Paramsothy, Founder of Hera Fertility. “Clinical validation with Mayo Clinic’s data infrastructure gives our AI models the opportunity to prove their accuracy and utility against the standard that clinicians and patients need to see before a technology becomes part of how fertility care is actually delivered. This program is the pathway from promising tool to clinically proven solution.”
Hera Fertility’s platform applies AI for male fertility to semen analysis data to generate fertility probability assessments that go beyond the categorical outputs of standard analyses. The company’s SmartScore tool converts semen analysis parameters into a numerical probability score, providing clinicians and patients with a more intuitive representation of fertility potential than raw parameter values alone. Clinical validation through the Mayo Clinic Platform Accelerate program will assess the predictive accuracy of that scoring model against outcomes data, establishing the evidence base necessary for clinical adoption.
The company provides male fertility testing in New York and is expanding its clinical partnerships across North America as the validation work progresses. New York’s concentration of fertility clinics, academic medical centres, and health technology investment makes it a strategically important market for a company building evidence-based AI tools for reproductive medicine. Hera Fertility’s presence in that market provides access to clinical partners and patient populations that support both ongoing research and commercial deployment of validated tools.
The application of AI to male fertility assessment reflects a broader trend in reproductive medicine toward data-driven diagnostic tools that supplement rather than replace clinical judgment. Fertility clinicians managing complex cases benefit from decision-support tools that surface patterns in patient data that may not be apparent through conventional analysis, particularly in cases where standard semen analysis results fall within ambiguous ranges that do not clearly indicate either normal fertility or significant impairment. Hera Fertility’s AI approach targets precisely that diagnostic grey zone, where additional analytical precision has the greatest potential to improve clinical decision-making.
About Hera Fertility: Hera Fertility is a health technology company founded by Thiv Paramsothy that develops AI-driven assessment tools for male fertility evaluation. The company has been selected for the Mayo Clinic Platform Accelerate program to clinically validate its AI models using Mayo Clinic’s clinical data infrastructure. Hera Fertility provides male fertility testing services and is advancing the clinical validation of its SmartScore tool, which converts semen analysis data into a fertility probability score for use in clinical and direct-to-consumer fertility assessment.
###
For more information about Hera Fertility, contact the company here:
Hera Fertility
Thiv Paramsothy
(888) 850-0919
support@herafertility.co
1178 Broadway, 3rd floor, 3092, New York, NY 10001, United States
